Public Profile

BonGeo Pharmaceuticals Inc.

BonGeo Pharmaceuticals Inc., headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for chronic diseases. Founded in 2010, the company has made significant strides in research and development, focusing on areas such as oncology and autoimmune disorders. With a commitment to advancing healthcare, BonGeo Pharmaceuticals offers a unique portfolio of biologics and small molecule drugs that stand out for their efficacy and safety profiles. The company has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its market position. Recognised for its dedication to quality and innovation, BonGeo Pharmaceuticals continues to expand its operational reach, aiming to improve patient outcomes globally while maintaining a strong presence in the US and other key markets.

DitchCarbon Score

How does BonGeo Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

3

Industry Average

Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

0

Industry Benchmark

BonGeo Pharmaceuticals Inc.'s score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

BonGeo Pharmaceuticals Inc.'s reported carbon emissions

BonGeo Pharmaceuticals Inc., headquartered in the US, currently does not have any publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). Additionally, there are no documented climate commitments or initiatives aimed at reducing greenhouse gas emissions. As the pharmaceutical industry increasingly focuses on sustainability, BonGeo Pharmaceuticals may need to establish clear climate commitments to align with industry standards and expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. BonGeo Pharmaceuticals Inc.'s primary industry is , which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. BonGeo Pharmaceuticals Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

BonGeo Pharmaceuticals Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Aytu BioPharma, Inc.

US
Health and social work services (85)
Updated 7 days ago

Method Pharmaceuticals, LLC

US
Chemicals nec
Updated 7 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers